| SLE | RA | T2DM | P-value |
---|---|---|---|---|
 | n = 123 | n = 100 | n = 3691 |  |
Age, years Median (IQR) | 34.5 (26.7, 47.7) | 60.5 (52.6, 66.8) | 63.3 (53.7, 71.7) | <0.001 |
Gender (% female) | 109 (89) | 88 (88) | 2,686 (73) | <0.001 |
Race/Ethnicity (%) | Â | Â | Â | Â |
   African-American | 46 (39) | 32 (34) | 1,252 (36) |  |
   Hispanic | 39 (33) | 42 (45) | 1,176 (34) | 0.199 |
   Other | 34 (29) | 20 (21) | 1,046 (30) |  |
   Unknown | 14 (12%) | 16 (16%) | 217 (6%) |  |
25OHD, ng/ml | Â | Â | Â | Â |
Median (IQR) | 18.0 (11.3, 25.4) | 20.9 (16.1, 29.9) | 16.8 (11.1, 24.2) | 0.0001 |
Season (%) | Â | Â | Â | Â |
   April-September | 61 (50) | 50 (50) | 1,698 (46) | 0.47 |
Serum creatinine >1.5 mg/dl (%) | 16 (13) | 2(2) | 855 (27) | <0.001 |
Serum calcium, mg/dl | Â | Â | Â | Â |
Median (IQR) | 9.2 (8.9, 9.5) | 9.5 (9.1, 9.7) | 9.6 (9.2, 10) | 0.001 |
Bisphosphonates use (%) | 20 (16) | 34 (34) | 346 (9) | <0.001 |
Calcium supplementation (%) | 60 (49) | 59 (59) | 864 (23) | <0.001 |
Prednisone use (%) | 85 (69) | 65 (65) | 231 (6) | <0.001 |
Vitamin D supplementation (%) | 57 (46) | 56 (56) | 867 (23) | <0.0001 |